Maslinic Acid Enhances Docetaxel Response in Human Docetaxel-Resistant Triple Negative Breast Carcinoma MDA-MB-231 Cells via Regulating MELK-FoxM1-ABCB1 Signaling Cascade
Docetaxel (DOC) is the most important chemotherapeutic drug for the treatment of triple negative breast cancer (TNBC); however, acquired drug resistance upon the long-term treatment limits its therapeutic effect. Maslinic acid (MA), a natural triterpene from Olea europaea L., attracts increasing int...
Main Authors: | Ke Wang, Xue Zhu, Yongxiang Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00835/full |
Similar Items
-
Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer
by: Hai-Hong Zhou, et al.
Published: (2019-12-01) -
Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma
by: Liang Chen, et al.
Published: (2020-01-01) -
FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A
by: Hongbo Yu, et al.
Published: (2020-11-01) -
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
by: Yubao Wang, et al.
Published: (2014-05-01) -
The Effects on Proliferation of siRNA-Mediated GLS1 Inhibition in MDA-MB 231 Breast Cancer Cells
by: Sakine Akar, et al.
Published: (2019-12-01)